A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome
Principal Investigator
Christopher FordyceOverview
Study Start/End
Jun 29, 2018 to Oct 31, 2021Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Shirley Lim, Research CoordinatorPhone
604-875-4065Email Address
shirley.lim@vch.caPurpose of Study
The purpose of this study is to test the safety and efficacy of a new drug (CSL112, also known as Apolipoprotein A-I) in participants with acute coronary syndrome.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.